Nakamura T, Higashi S, Tomoda K, Tsukano M, Baba S, Shono M
Section of Internal Medicine and Rheumatology, Kumamoto Center for Arthritis and Rheumatology, 1-15-7 Kuhonji, Kumamoto 862-0976, Japan.
Rheumatology (Oxford). 2006 Jan;45(1):43-9. doi: 10.1093/rheumatology/kei112. Epub 2005 Oct 11.
To clarify the clinical significance of the SAA1.3 allele in the development and outcome of AA amyloidosis in Japanese patients with rheumatoid arthritis (RA).
One hundred and twenty RA patients (60 alive and 60 dead) fulfilling the 1987 ACR criteria and 62 RA patients with biopsy-confirmed amyloid A (AA) amyloidosis (36 alive and 26 dead) were enrolled. The SAA1 genotypes were determined by PCR-based restriction fragment length polymorphism. To predict the clinical outcome of AA amyloidosis, we investigated characteristics and survival, focusing on the SAA1.3 allele retrospectively.
The SAA1.3 allele genotype was not only a risk factor for the association of AA amyloidosis but also a poor prognostic factor for the development of AA amyloidosis (P=0.015). Both the association of AA amyloidosis arising early in the RA disease course and symptomatic variety and severity were found in amyloidotic patients with the SAA1.3 allele. The presenting factors adversely influenced were age (P=0.001), lowered serum albumin (P=0.001) and creatinine concentration (P=2.14 x 10(-5)). Renal involvement was associated with poor survival in patients with AA amyloidosis (P=0.011) and the presence of cardiac involvement was likely to be a risk factor for survival (P=0.062). The rate of the causes of death in respect to the category of infection, gastrointestinal diseases, and renal failure was higher in patients with AA amyloidosis than in those without amyloidosis, gastrointestinal diseases and renal failure. Cyclophosphamide was found to be superior to methotrexate in the management of RA patients with AA amyloidosis.
Our data support the fact that homozygosity for the SAA1.3 allele is a univariate predictor of survival in addition to a risk factor for the association of AA amyloidosis adversely influencing the outcome in Japanese RA patients. Renal involvement is a pivotal clinical manifestation in the development of AA amyloidosis, as is likely to be cardiac involvement in AA amyloidosis secondary to RA.
阐明SAA1.3等位基因在日本类风湿关节炎(RA)患者AA淀粉样变性的发生及预后中的临床意义。
纳入120例符合1987年美国风湿病学会(ACR)标准的RA患者(60例存活,60例死亡)以及62例经活检确诊为淀粉样蛋白A(AA)淀粉样变性的RA患者(36例存活,26例死亡)。通过基于聚合酶链反应(PCR)的限制性片段长度多态性分析确定SAA1基因型。为预测AA淀粉样变性的临床结局,我们回顾性研究了以SAA1.3等位基因为重点的特征及生存情况。
SAA1.3等位基因基因型不仅是AA淀粉样变性关联的危险因素,也是AA淀粉样变性发生的不良预后因素(P=0.015)。在携带SAA1.3等位基因的淀粉样变性患者中,发现AA淀粉样变性在RA病程早期出现的关联以及症状的多样性和严重程度。产生不利影响的呈现因素为年龄(P=0.001)、血清白蛋白降低(P=0.001)和肌酐浓度(P=2.14×10⁻⁵)。肾脏受累与AA淀粉样变性患者的不良生存相关(P=